IngredientsCaprylic acid — from the Latin capra, meaning "goat" — is also known under the systematic name octanoic acid, or C8 acid; it is a saturated, medium-chain fatty acid (MCFA). Chemically, it carries the molecular formula C₈H₁₆O₂ and consists of a saturated fatty acid with an eight-carbon chain. Its structural formula is H₃C−(CH₂)₆−COOH, and it is a colorless oily liquid that is minimally soluble in water with a slightly unpleasant rancid-like smell and taste.
Salts and esters of octanoic acid are known as octanoates or caprylates, and the related acyl group is called octanoyl, capryloyl, or caprylyl. Notably, caprylic acid is a straight-chain isomer of the well-known antiepileptic drug valproic acid.
Caprylic acid's compounds are found naturally in the milk of various mammals and as a minor constituent of coconut oil and palm kernel oil. Two other acids are named after goats via the Latin word capra — caproic acid (C6) and capric acid (C10) — and together these three fatty acids comprise approximately 15% of the fatty acids in goat milk fat. Dairy products and specific oils like coconut oil are natural sources of dietary C8:0, but higher intakes of this fatty acid can be provided with MCT (medium-chain triglyceride) oil, which consists of approximately 75% C8:0.
Caprylic acid is commercially available in several forms. Caprylate can be consumed as tricaprylin/tricaprylate (also called trioctanoate), a medium-chain triglyceride (MCT). It is also available over the counter and can be present in many skincare products; it is one of the three main ingredients in medium-chain triglyceride (MCT) dietary supplements. As a standalone supplement it is sold in capsule, softgel, and liquid oil form. MCT oil is comprised primarily of caprylic (C8:0) and capric (C10:0) acids with a very small percentage of caproic (C6:0) and lauric (C12:0) acids, all esterified to a glycerol backbone.
Caprylic acid, a naturally occurring eight-carbon fatty acid, has long been used as an albumin stabilizer, non-IgG fraction precipitant, and bactericidal agent in the pharmaceutical industry. Commercially, it is produced by oxidation of the C8 aldehyde.
The antimicrobial potential of caprylic acid was first reported in the scientific literature in the 1940s and 1950s. Prior to its clinical characterization, populations in regions with high consumption of coconut oil and goat's milk — including tropical and subtropical cultures — consumed caprylic acid as a naturally occurring dietary constituent, though specific ethnobotanical records attributing targeted medicinal use directly to caprylic acid (as distinct from the whole food sources) are limited in the peer-reviewed record.
Beneficial physiological effects of dietary C8:0 have been studied for a long time, and MCT oil has been used as a special energy source for patients suffering from pancreatic insufficiency, impaired lymphatic chylomicron transport, and fat malabsorption. This early clinical application — administering MCT-rich preparations to patients who could not adequately absorb conventional long-chain dietary fats — represents one of the earliest documented therapeutic uses of caprylic acid-containing preparations in Western medicine.
Caprylic acid's historical applications as an albumin stabilizer, non-IgG fraction precipitant, and bactericidal agent are well-established in the pharmaceutical industry. These pharmaceutical uses predate its adoption as a consumer dietary supplement and reflect a long history of recognition of its protein-binding and antimicrobial properties.
In the mid-twentieth century, interest in caprylic acid for intestinal fungal overgrowth was documented in the clinical literature. A 1954 paper cited in multiple reference databases reported successful treatment of intestinal moniliasis (a candidal infection) with a fatty acid resin complex, a preparation that included caprylic acid. This early use laid the groundwork for the later supplement-industry positioning of caprylic acid as an antifungal agent.
Caprylic acid (C8H₁₆O₂) is a saturated fatty acid consisting of an eight-carbon chain; it is an oily, clear, and colorless liquid with a rancid odor, minimal solubility in water, and a weak acidic character. At physiological pH, the free fatty acid predominantly exists in ionized form due to its pKa of 4.89.
The metabolic behavior of caprylic acid is fundamentally distinct from that of long-chain fatty acids (LCFAs), and this distinction underlies many of its proposed physiological roles. MCTs containing caprylic acid are partially hydrolyzed in the stomach by lingual lipase and by pancreatic lipase in the intestinal lumen, with subsequent absorption of medium-chain fatty acids via the portal vein to the liver, where MCFAs are catabolized mainly to C2 fragments or utilized to synthesize longer-chain fatty acids.
MCFAs are more rapidly absorbed from the gut directly to the liver via the portal vein compared to long-chain fatty acids, which are absorbed primarily via the lymphatic duct and into the peripheral circulation. Medium-chain fatty acids do not rely on membrane transporters for uptake into cells and can be directly transported to the mitochondrial intermembrane space without the carnitine shuttle.
The fraction of caprylic acid not used by the enterocyte leaves the cell without being incorporated into chylomicrons; instead, it passes directly into the capillaries of the portal circulation, where it is mostly bound to the plasma protein albumin, from there reaching the liver, where it is absorbed and rapidly metabolized. Because it is not incorporated into chylomicrons, it bypasses the lymphatic circulation, making it unlikely for the fatty acid to be stored in adipose tissue.
Caprylic acid undergoes hepatic metabolism to form β-hydroxybutyrate, a ketone body, which serves as a substitute form of energy for brain cells. Very little acetyl-CoA enters the citric acid cycle in the liver since the intermediates oxaloacetate and malate are consumed for glucose production; the high amount of NADH also allosterically inhibits the citric acid cycle, with the result that metabolism of medium-chain fatty acids promotes the generation of ketones.
Caprylic acid is a weak acid with a low pKa (4.89) that penetrates bacterial cell membranes via passive diffusion and reduces cytosolic pH, likely by stimulating H⁺-ATPase activity and thereby lowering bacterial cell vitality. Fatty acids exert their antimicrobial actions by targeting different cellular functions, including protein synthesis, fatty acid metabolism, and even topoisomerase activity.
Caprylic and capric acids have been shown to inhibit processes involved in Candida albicans virulence such as morphogenesis, adhesion, and biofilm formation; however, their primary mode of antifungal action is through membrane perturbations in the target organism. The mechanisms through which caprylic acid achieves its effects have been correlated with the molecule's protein/lipid binding capacity, conferred by its octyl moiety.
Caprylic acid has been shown to acylate ghrelin, the only known peptide hormone with an orexigenic (appetite-stimulating) effect; through its covalent binding to the ghrelin peptide, caprylic acid exhibits an emerging and specific role in modulating physiological functions regulated by octanoylated ghrelin. Dietary caprylic acid is therefore now suspected to provide the ghrelin O-acyltransferase (GOAT) enzyme with octanoyl-CoA co-substrates necessary for the acyl modification of ghrelin.
Ghrelin stimulates hunger by triggering receptors in the hypothalamus; in order to activate these receptors, ghrelin must undergo a process called acylation in which it acquires an acyl group, and caprylic acid provides this by linking at a specific serine site on ghrelin molecules.
In vitro, decanoic acid (the C10 MCFA also present in MCT oil) is more potent than valproic acid, which is a branched-chain fatty acid isomer of octanoic acid commonly used in the treatment of epilepsy. This structural kinship places caprylic acid in a pharmacologically interesting chemical family, though its direct anticonvulsant mechanism differs from valproate's.
There exists a substantial body of literature describing antimicrobial effects of medium-chain fatty acids against a plethora of bacteria and fungi; Candida albicans appears to be uniquely sensitive to fatty acids with carbon chain lengths of C8, C10, and C12, represented by caprylic, capric, and lauric acid, respectively. As early as the 1960s, Tsukahara demonstrated that caprylic acid was a robust, fast-acting fungicide; treatment of C. albicans with caprylic acid at even relatively low concentrations (e.g., 10⁻⁵ M) led to total killing in as little as 10 minutes of contact time.
In vitro studies have consistently demonstrated that caprylic acid and lauric acid (MCFAs) have potential anticandidal activity against C. albicans. A study published in the Biomedical and Biotechnology Research Journal comparing these MCFAs with clotrimazole found that these MCFAs showed less variation with almost equal potency to currently used azoles and were preferred instead of azoles for their advantages of less resistance, lower cost, and minimal side effects. However, future clinical trials are required to evaluate these MCFAs against clinical infections caused by Candida.
In a 2025 in vitro study using a three-dimensional fibrin gel wound biofilm model, a combination of polygalacturonic acid and caprylic acid (PG + CAP) reduced C. parapsilosis by 4.88 log₁₀ and C. albicans by 5.76 log₁₀ relative to control, and was able to completely eradicate C. auris; the antimicrobial superiority of PG + CAP relative to hypochlorous acid was statistically significant (p ≤ 0.05) against multiple Candida species tested.
Evidence strength: The antifungal evidence for caprylic acid is predominantly in vitro and preclinical. Mechanistic data are well-established, but controlled human clinical trials specifically assessing oral caprylic acid supplementation for candidal infections are not yet available in the peer-reviewed record. The evidence base currently supports caprylic acid's antifungal properties as a topical or laboratory agent; evidence for systemic antifungal benefit in humans remains preliminary.
A 2025 review in Metabolites (PMC) investigated the bactericidal and anticancer potential of caprylic acid against Helicobacter pylori infection, a major global risk factor for gastric cancer, noting that several carcinogenic mechanisms induced by this bacterium remain incompletely understood. Caprylic acid, a medium-chain fatty acid naturally found in coconut oil and goat's milk, possesses notable biological properties that may confer gastroprotective effects against gastric cancer induced by H. pylori.
Caprylic acid exhibited maximal bactericidal effects at 1 mM within pH 2.5–3.0, at 10 mM within pH 4.0–4.5, and at 20 mM at pH 5.0; these discrepancies underscore the influence of experimental conditions, particularly pH, on the antimicrobial activity of caprylic acid. Research published in Pathogens and Disease screened saturated fatty acids including caprylic acid (C8:0) for antibacterial activity against H. pylori alongside a range of other chain-length fatty acids and monoglycerides.
Evidence strength: The evidence for caprylic acid's activity against H. pylori and other bacteria (including E. coli and Salmonella) is primarily in vitro. Peer-reviewed reviews published in 2025 treat this as a promising but not yet clinically validated area requiring further human trials.
The MCT ketogenic diet was first identified as a treatment for refractory epilepsy in 1971; it has provided one of the most effective therapeutic approaches for children with drug-resistant epilepsy and has been demonstrated to be effective in childhood epilepsy in a randomized controlled trial.
Recent studies suggest MCFAs confer anticonvulsant effects: caprylic acid (C8, also known as octanoic acid) and capric acid (C10, also known as decanoic acid) both exerted anticonvulsant effects when administered adjunctively to a normal diet in animal studies. However, when examining the direct mechanism, research published in Brain (Oxford Academic, 2016) found that octanoic acid did not affect epileptiform discharges in vitro at a concentration of 1 mM and also failed to affect AMPA receptor currents in Xenopus oocytes. In contrast, it has been established that decanoic acid, but not octanoic acid, has anti-seizure effects at clinically relevant concentrations in vitro and in vivo. Octanoic acid had no effect on AMPA receptor currents, suggesting that octanoic acid is unlikely to have a direct effect on seizure control through AMPA receptor inhibition.
One major component of MCT is caprylic acid; MCT supplementation while maintaining a regular diet demonstrated increased ketosis, suggesting a possible role in the treatment of epilepsy. A case report documented a 43-year-old patient with drug-resistant epilepsy who experienced marked seizure reduction after MCT oil supplementation; MCT oil supplementation to regular diet may provide better seizure control in some patients and may be a more tolerable alternative to the standard ketogenic diet.
Evidence has been reviewed including tolerance in 65% of humans, efficacy studies in dogs, and possible anticonvulsant mechanisms of MCTs; MCTs are considered a promising adjunct to standard pharmacological treatment for both humans and dogs with epilepsy, as they lack central nervous system side effects found with current antiepileptic drugs, though there is a need for larger clinical trials in children, adults, and dogs to find the ideal composition and doses of MCTs and the types of epilepsy that respond best.
Evidence strength: The MCT ketogenic diet as a whole has Class I clinical evidence in pediatric epilepsy (randomized controlled trial). Caprylic acid's individual contribution to anticonvulsant effects within MCT preparations is less clearly established than that of capric acid (C10), based on current in vitro and in vivo mechanistic data. Its anticonvulsant role is likely mediated indirectly via ketone body production rather than direct AMPA receptor interaction.
Of particular relevance to clinical trials assessing ketogenic interventions for neurodegenerative disorders is the oral ketogenic compound AC-1202 (marketed as "Axona"), which includes caprylic acid, a medium-chain triglyceride. It is a dietary supplement studied in Phase 2 clinical trials (Henderson et al., 2009) for Alzheimer's disease.
The BENEFIC trial provided Class II evidence for the efficacy of a ketogenic MCT formula (a 12% emulsion comprised of 60% caprylic acid [C8] and 40% capric acid [C10], in lactose-free skim milk) in mild cognitive impairment. A supplemental PET imaging study found that supplementation with an MCT formula comprised of 55% caprylic acid and 35% capric acid increased total brain metabolism in Alzheimer's disease (a trend driven by increased ketone body uptake, as glucose uptake remained unchanged).
Caprylic acid has been studied in a small number of people with cognitive impairment, including some people with Alzheimer's disease; it does not seem to reverse established cognitive impairment. There is some data to show that higher levels of caprylic acid may be associated with a reduced risk of cognitive impairment, but it is not clear if taking caprylic acid supplements is linked with a reduced risk of cognitive impairment. The benefits of taking caprylic acid for brain health are not well defined.
Ketogenic nutritional interventions are validated treatments of pharmacoresistant epilepsy; however, in neurodegenerative diseases and cognitive decline, the potential benefits were previously pointed out, but the published evidence remains scarce.
Evidence strength: Early Phase 2 clinical trial data and Class II evidence exist for MCT formulations containing caprylic acid in mild cognitive impairment and Alzheimer's disease. These studies suggest a mechanism (ketone-mediated alternative brain fuel) is biologically plausible, but the evidence base is limited in size and scope, and caprylic acid has not been shown to reverse established Alzheimer's disease pathology. Larger, well-controlled trials are needed.
It is commonly known that medium-chain triglycerides (MCTs) are administered to patients with gastrointestinal disorders such as Crohn's disease or short-bowel syndrome; little is currently known as to the mechanism behind the effects of MCT on intestinal inflammation. One study examined whether caprylic acid and MCT suppress IL-8 secretion by differentiated inflammatory Caco-2 cells; upon completion, it was noted that caprylic acid and MCT suppressed IL-8 secretion by the Caco-2 cells at a transcriptional level when pre-cultured for 24 hours; a dual-luciferase assay further revealed that caprylic acid inhibited the activation of the IL-8 promoter.
Evidence strength: Anti-inflammatory activity in the gastrointestinal tract has been demonstrated in cell culture (in vitro) studies. Human clinical evidence in intestinal inflammatory conditions is absent in the peer-reviewed literature reviewed here; this area remains preclinical and hypothesis-generating only.
Beneficial physiological effects of dietary C8:0 have been studied for a long time; MCT oil has been used as a special energy source for patients suffering from pancreatic insufficiency, impaired lymphatic chylomicron transport, and fat malabsorption. MCFAs treatments (C6, C8, and C10) maintained optimal insulin sensitivity and even fostered basal and insulin-dependent phosphorylation of the Akt-mTOR pathway; overall, MCFAs could constitute an effective nutritional tool to manage liver steatosis and hepatic insulin resistance.
Beta-hydroxybutyrate and MCFAs help β-cells recover from lipotoxic stress by improving mitochondrial function and increasing the expression of genes involved in β-cell function and insulin biogenesis; MCFAs offer a therapeutic advantage in the preservation of β-cell function as part of a preventative strategy against diabetes in at-risk populations (Augustin et al., 2018).
Evidence strength: The use of MCT preparations (containing caprylic acid) as a dietary fat source for patients with fat malabsorption syndromes is well-established clinical practice. The metabolic data on insulin sensitivity and β-cell function derive primarily from in vitro and animal models; prospective human clinical trials focused specifically on caprylic acid in these contexts are limited.
A published review highlighted the discrepancy between the formerly described beneficial effects of dietary MCFAs on body weight loss and the newly reported effect of C8:0 on appetite stimulation via ghrelin octanoylation, noting the relevance of carrying out further studies to better understand the physiological functions of this particular fatty acid. Diet is suspected to directly provide the GOAT enzyme with caprylic acid, subsequently activated as octanoyl-CoA co-substrate necessary for the O-acylation of ghrelin; ingestion of MCFAs/MCTs in mice increased stomach acylated ghrelin concentration without modifying total ghrelin level.
A diminished deposition of fat was reported in rats overfed with MCT diets compared with LCT diets. These studies suggest that GOAT might be a therapeutic target against obesity and hyperphagia through inhibition of its activity to decrease the circulating level of acylated ghrelin.
Evidence strength: Animal studies suggest reduced fat deposition on MCT-rich diets. The ghrelin octanoylation data from rodent models introduce a paradox — caprylic acid may both be associated with reduced fat storage and with increased appetite hormone activation. Human data on caprylic acid specifically for weight management are insufficiently robust to draw firm conclusions; the evidence is preliminary and mechanistically complex.
In medical research, caprylic acid appears to have potential as an adjuvant in the treatment of high-grade glial tumors; these tumor cells, due to defective mitochondria, rely on anaerobic glycolysis even in the presence of oxygen and are unable to metabolize ketone bodies; a treatment based on therapeutic ketosis has therefore been proposed for glioblastoma multiforme, and caprylic acid is among the best precursors of ketone bodies and, in vitro and at high doses, has been shown to induce tumor necrosis. Caprylic acid induces tumor cell necrosis and crosses the blood-brain barrier.
Evidence strength: Highly preliminary; this area is limited to in vitro data and theoretical mechanistic arguments at this time. No human clinical trials have established caprylic acid as an oncological treatment.
Doctors have sometimes recommended amounts of 500 to 1,000 mg three times a day for caprylic acid supplementation, based on historical clinical use for intestinal candidiasis.
In the Alzheimer's disease context, the BENEFIC trial used a 12% emulsion of a formula comprised of 60% caprylic acid (C8) and 40% capric acid (C10) in lactose-free skim milk.
A large oral dose of MCTs (approximately 20 mL to 40 mL) will result in sustained hyperketonemia, reflecting the dosing range used in ketogenic nutritional protocols containing caprylic acid.
In epilepsy research, gavage of 20 mmol/kg octanoic acid in rodent models produced around 400 µmol/L octanoate and increased β-hydroxybutyrate from 0.28 mmol/L to 0.9 mmol/L in blood, establishing a dose–ketone relationship in animal systems. Human dosing equivalents have not been directly derived from this model.
Caprylic acid is available in capsule, softgel, and liquid oil formats for supplemental use. Humans have no established nutritional requirement for caprylic acid, so deficiency is not physiologically possible.
Caprylic acid is likely safe for most people when taken by mouth in food amounts or when used at approved doses for nutritional supplementation and in tests to measure stomach emptying; it can cause some side effects, including nausea, bloating, and diarrhea. It is possibly safe when taken as part of a ketogenic diet or a diet high in MCTs under physician guidance; however, diets containing high amounts of caprylic acid might cause constipation, vomiting, stomach pain, low levels of calcium in the blood, drowsiness, or growth problems.
Caprylic acid is considered likely unsafe when taken by mouth by people with a condition known as medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, as people with this condition are not able to break down caprylic acid appropriately. In patients with MCAD deficiency, the plasma contains partially oxidized medium-chain fatty acids, including octanoic acid. Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is the most common inherited defect of fatty acid beta-oxidation.
The more common side effects from caprylic acid supplementation include nausea, constipation, diarrhea, heartburn, acid reflux/indigestion, bloating, vomiting, gastrointestinal pain, and hypocalcemia; some test subjects in the 2009 Alzheimer's disease study (using AC-1202) were noted to experience bouts of diarrhea due to the administered supplement.
At the time of documented review, there were no well-known supplement or food interactions with caprylic acid, and no reported interactions between caprylic acid and medicines were identified. Extra care is advised when taking caprylic acid in combination with drugs that lower blood pressure, such as atenolol, captopril, furosemide, losartan, hydrochlorothiazide, nifedipine, or prazosin. Extra care is also warranted when taking it with drugs used for swelling or inflammation, which can also increase the risk of bleeding; these include NSAIDs, aspirin, ibuprofen, or naproxen.
Research on the co-administration of capric acid (the C10 MCFA closely related to caprylic acid) with conventional antifungal drugs has revealed important complexities. Capric acid co-administered with fluconazole inhibits the activity of the Cdr1 transporter, suggesting a potentially synergistic effect with azole drugs; conversely, treatment with capric acid leads to overproduction of ergosterol in C. albicans cells, leading to cross-resistance towards amphotericin B. These findings from related MCFAs raise important questions about potential pharmacodynamic interactions that have not yet been formally characterized for caprylic acid in clinical settings.
Due to the lack of research, little is known about the long-term use of supplementation with caprylic acid; currently, the only known side effects related to supplementation and consumption are related to either excessive consumption or use with hepatobiliary-related conditions or inflammation.
Health conditions that Caprylic acid may help support.
Gastrointestinal side effects—including nausea, cramping, and diarrhoea—are the most consistently documented adverse effects of caprylic acid and MCT oil in human studies. These are dose-dependent and occur particularly when taken on an empty stomach. This well-documented tolerability profile means the gut relationship is scientifically established, though it is an adverse effect rather than a therapeutic benefit.
MCT intake (including C8) reduces subsequent ad libitum energy intake compared to long-chain fats in controlled trials, suggesting an effect on satiety. However, caprylic acid also acylates ghrelin, the hunger-stimulating hormone, creating a mechanistic tension. Net effect on appetite in human trials favors mild suppression when MCTs replace LCTs.
Rxlist/WebMD-level regulatory sources note that caprylic acid might lower blood pressure in some people, but this claim is based on very limited and indirect evidence. No dedicated human RCT establishes blood pressure lowering as a defined effect. The rating 'scientific' is marginal; the evidence is more mechanistic/observational than clinical.
Caprylic acid's rapid conversion to ketones provides an alternative cerebral energy source that may transiently relieve cognitive sluggishness (brain fog) associated with cerebral glucose hypometabolism. Human data supporting this are mostly indirect, derived from MCT/ketone trials in aging and mild cognitive impairment cohorts. Acute benefits within 90 minutes of a C8 dose are reported.
Caprylic acid is an eight-carbon medium-chain fatty acid from coconut oil that disrupts the lipid membranes of Candida cells, causing cell death and inhibiting hyphal growth and biofilm formation in vitro. Multiple laboratory studies confirm antifungal activity against C. albicans. A pediatric RCT found MCT supplementation (including caprylic acid) reduced Candida gastrointestinal colonization in preterm infants.
Caprylic acid (octanoic acid), a medium-chain fatty acid found in coconut oil, has demonstrated antifungal activity against Candida albicans in multiple in vitro studies by disrupting fungal cell membranes and inhibiting hyphal transition and biofilm formation. A 2019 clinical trial in preterm infants showed dietary caprylic/capric acid supplementation produced a highly significant reduction in intestinal Candida burden (rate ratio 0.15; p=0.02), with rapid rebound upon cessation. It is among the most commonly used natural antifungals in Candida cleanse protocols.
Caprylic acid is rapidly converted in liver mitochondria to ketone bodies that enter the TCA cycle directly, bypassing glycolysis, to generate ATP. This is the fundamental mechanism behind MCT use in clinical nutrition for malabsorptive conditions and in ketogenic therapies. Human pharmacokinetic studies confirm efficient ketone production from C8.
A 2015 meta-analysis of 13 RCTs found MCTs (C8/C10) did not significantly alter total cholesterol, LDL, or HDL overall versus LCTs. Animal data show caprylic acid may improve lipid metabolism via ABCA1 upregulation and reduced inflammatory lipid deposition. Human lipid effects of caprylic acid alone are small and inconsistent.
In Alzheimer's disease the brain develops glucose hypometabolism; ketones derived from caprylic acid provide an alternative fuel. Small human trials of MCT formulas containing caprylic acid show improvements in cognitive assessment scores, particularly in APOE4-negative patients. Evidence is promising but limited to small, short studies.
Caprylic acid is rapidly absorbed via the portal vein, bypassing lymphatic transport, and is efficiently converted to ketone bodies in liver mitochondria. Human crossover studies confirm C8 produces a significantly greater ketogenic (plasma beta-hydroxybutyrate) response than C10 or C12, providing a fast-acting alternative fuel source. This underpins its clinical use in fat-malabsorption syndromes and its popular use as an energy supplement.
Caprylic acid (C8) is the principal active fatty acid in the medium-chain triglyceride ketogenic diet (MCT-KD), a clinically established therapy for drug-resistant epilepsy. Animal studies confirm direct anticonvulsant activity independent of ketosis, and it potentiates valproate. Human use of the MCT-KD is supported by decades of paediatric clinical experience, though large RCTs specific to caprylic acid alone remain limited.
Caprylic acid, a medium-chain fatty acid from coconut oil, has in vitro and computational evidence of antifungal action against Candida species and Trichophyton by penetrating and perturbing fungal cell membranes. A 2019 study found it effective at killing Candida albicans. A PMC study (2020) demonstrated it disrupts fungal membranes via steady-state fluorescence anisotropy and is potent against Candida and Trichophyton. It also inhibits virulence factors including morphogenesis and biofilm formation.
Caprylic acid is naturally produced in the gut by anaerobic microbial fermentation and is found at lower levels in IBD patients compared to healthy controls, suggesting it is a marker of a healthy microbiome. In vitro and animal data show antimicrobial selectivity against pathogens including Candida, while preclinical MCT studies show increases in beneficial Akkermansia. Human interventional data are limited.
A meta-analysis of 13 RCTs (n=749) found that MCTs (principally C8 and C10) versus long-chain triglycerides produced a small but significant reduction in body weight (−0.51 kg) and waist circumference (−1.46 cm). Effects are modest and additive to caloric restriction rather than standalone. A retrospective study found MCT supplementation enhanced weight loss on a VLCKD.
Early preclinical and in vitro evidence suggests caprylic acid and MCTs support intestinal barrier function under inflammatory conditions. Animal MCT studies show reduced intestinal permeability and increased Akkermansia abundance. Human-specific evidence is limited to indirect observations from clinical nutrition and IBD metabolomics studies.
MCT oil formulas rich in caprylic acid have shown improvements in working memory and episodic memory in small human trials, most notably in older adults and those with mild cognitive impairment. The mechanism involves ketone-based alternative cerebral fueling. Effects appear strongest when baseline memory is already declining.
Caprylic acid enters liver mitochondria independently of carnitine and generates ketone bodies that fuel mitochondrial ATP synthesis via the TCA cycle. In vitro studies show C8 activates respiratory chain enzyme complexes in hippocampal neurons. Animal data show neuroprotective effects via increased mitochondrial oxygen consumption. Primary human evidence comes from ketogenic diet and MCT studies.
Huang et al. (2011, Archives of Oral Biology) demonstrated that short and medium-chain fatty acids, including caprylic acid, exhibit antimicrobial activity against oral microorganisms including Candida and cariogenic bacteria. Caprylic acid shows anticandidal activity in vitro with MIC values relevant to oral concentrations. Clinical oral use evidence remains primarily in vitro and traditional.
Athlete's foot (tinea pedis) is caused by dermatophytes including Trichophyton species. Caprylic acid's broader antifungal mechanism (membrane disruption) has been demonstrated against Candida and related fungi. Caprylic acid derivatives have shown activity against Trichophyton in preclinical models. Traditional use involves coconut oil (rich in C8) topically for fungal foot infections; dedicated clinical trials are absent.
Caprylic acid's antifungal and antimicrobial properties lead to its use by integrative practitioners for IBS cases believed to involve Candida overgrowth or dysbiosis. Caprylic acid is depleted in IBD stool metabolomics. No RCT has directly tested caprylic acid for IBS symptom relief; the clinical use is based on the Candida–IBS hypothesis and practitioner experience.
Caprylic acid (octanoic acid, a medium-chain fatty acid from coconut oil) is used in natural parasite cleanse protocols for its proposed ability to disrupt Candida and parasite cell membranes. It appears in traditional antiparasitic supplement formulations and is listed in parasite-related herb databases.
Caprylic acid is used by integrative practitioners for small intestinal bacterial/fungal overgrowth based on its broad antimicrobial properties. Its selective activity against Candida and some bacteria, combined with rapid absorption via the portal vein before reaching the distal gut, makes the SIBO rationale less direct than for colonic overgrowth. No human RCT exists for this specific indication.
Caprylic acid's antifungal properties against Candida albicans—the primary cause of vulvovaginal candidiasis—have been established in vitro. Traditional and integrative practitioners use it for vaginal yeast management. Controlled human clinical trials assessing intravaginal caprylic acid are not published; the relationship is grounded in its documented antifungal mechanism and traditional use.
Body systems that Caprylic acid may help support.
Go back